SCHEMBL22266261

SCHEMBL22266261

NC(=O)CCCOCCCCO

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.57
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
GPR84 Q9NQS5 1/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
THRB P10828 1/20 0.37
HTT P42858 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 3/20 0.36
MAPK1 P28482 1/20 0.35
CAMK2A Q9UQM7 1/20 0.35
ACHE P22303 6/20 0.32
KDM4E B2RXH2 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22266252 0.93 GAA (0.66) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL22266272 0.93 GAA (0.55) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL22266236 0.93 GAA (0.66) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL22266240 0.93 GAA (0.48) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL20325130 0.91 GAA (0.58) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL22266255 0.91 GAA (0.57) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL22266248 0.88 GAA (0.60) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL10706576 0.88 GAA (0.60) GAACYP4F2CYP4A11GPR84FFAR1
SCHEMBL8883206 0.88 TSHR (0.50) GAACYP4F2CYP4A11MEN1KMT2A
SCHEMBL27819968 0.87 GAA (0.40) GAAMEN1KMT2ATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL GAA 1531/4885CYP4F2 2758/4885CYP4A11 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.